Sponsored, no-charge

genetic testing for faster

diagnosis of rare primary


X4 Pharmaceuticals, Inc. has partnered with Invitae to offer third-party sponsored genetic testing at no charge for individuals who may carry a genetic mutation known to be associated with severe chronic and/or congenital neutropenia (SCN), including WHIM syndrome.
Primary immunodeficiencies are a group of inherited disorders of the immune system including SCN and WHIM.

Program eligibility

Patients who meet the inclusion criteria (below) which suggest severe chronic/congenital neutropenia are invited to take part in the PATH4WARD program:

History of chronic severe neutropenia (ANC ≤ 500/uL), permanent or intermittent (cyclical), of unknown origin, AND with a clinical presentation compatible with chronic idiopathic neutropenia or severe congenital neutropenia.

Signs and symptoms

Severe congenital neutropenia (SCN) consists of a heterogeneous group of rare hematological diseases characterized by a selective decrease in circulating neutrophils, impaired maturation or trafficking, and higher risk of recurrent severe infections.1

  • SCN is a rare condition: its prevalence is estimated to be between 3 and 8.5 cases per million individuals. Molecular diagnosis is the best way to confirm the diagnosis, understand the disease, and determine possible treatment options in patients with chronic neutropenia.

  • One example of SCN associated with primary immunodeficiency is WHIM syndrome, a rare, autosomal dominant primary immunodeficiency disease caused by mutations in the CXCR4 gene leading to abnormal immune cell trafficking. Patients affected with WHIM may present with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. In addition, patients may experience frequent upper respiratory tract and systemic infections, often beginning in infancy and leading to life-threatening complications. Potentially fatal infections, such as meningitis and sepsis have been reported. Some patients with WHIM are at a higher risk for EBV-associated T and B cell lymphoproliferative disease and lymphoma. In addition, patients have an increased risk of malignancy due to human papillomavirus (HPV) transformation, leading to carcinoma.

Family variant testing

X4 and Invitae will also offer family variant testing (FVT) for all blood relatives of patients found to have a pathogenic or likely pathogenic variant, at no additional charge within 90 days of the original patient’s test. This service includes full analysis of the gene in which the original family member’s variant was identified.

To place an FVT order, download the paper order form.

Benefits of testing

The benefits of genetic testing include the ability to:

  • Identify risk of disease for patients and their family members
  • Shorten the time to diagnosis and help prevent misdiagnosis
  • Help patients and their physicians consider clinical trial options
  • Provide information about support services such as patient advocacy organizations

Program testing options

Initial program panel:

the PATH4WARD program uses the Invitae Severe Congenital Neutropenia Panel. This panel analyzes 23 genes known to be associated with severe congenital neutropenia.

View panel

Re-requisition panel:

Invitae Primary Immunodeficiency Panel. If the initial results come back negative, clinicians have the option to re-requisition to a broader panel. The Invitae PID Panel analyzes 207 genes that are associated with inherited disorders of the immune system.

View panel

Ordering made easy

Place your order Collect a specimen Results

To place a paper-based order, download the paper order form.

To collect a specimen:

  1. Order a free specimen collection kit
  2. Label the sample tube with the patient’s full name, date of birth, and sample collection date
  3. For additional information, see specimen and shipping requirements
  4. Include the paper order form with your sample

To receive results:

  1. Once Invitae receives the sample, you will receive the results in 10–21 calendar days, on average. 
  2. If you created an online account, you can view the status of your order and the sample results by logging into your account
  3. You will receive a notification email once the test results are ready

Support every step of the way

Client services

Available to answer your questions or help you through the testing process.



Sponsored genetic counseling

Individuals tested through the PATH4WARD program are eligible for post-test genetic counseling to help them understand their test results. This service is provided through GeneMatters, a third-party genetic counseling service, and is made available by Invitae at no charge as part of the program.

To schedule a genetic counseling appointment, please contact GeneMatters at 1-866-741-5331 or schedule online at https://www.gene-matters.com using partner code: PATH.


If you initially choose the Invitae Severe Congenital Neutropenia Panel panel and the initial results are negative, clinicians will be able to re-requisition to the broader Invitae Primary Immunodeficiency panel within 90 days of receiving the original results at no charge. No new specimen is required for negative test results.


Confidence begins with quality

  • Commitment to quality: Invitae’s >1000 patient peer-reviewed study, published in the Journal Molecular Diagnostics, the official journal of the Association for Molecular Pathology, shows equivalence to established standards.
  • Sample options: blood and saliva kits provided free of charge.
  • Strong team: Invitae has more than 300 experts in genetics, bioinformatics, engineering, technology, and commercial development.

About Invitae

Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene tests today.

About X4 Pharmaceuticals, Inc.

X4 is a clinical-stage biopharmaceutical company developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, mavorixafor (X4P-001), is expected to commence a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease, in the second quarter of 2019.

While X4 Pharmaceuticals, Inc. (X4 Pharma) provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. X4 Pharma receives de-identified patient data from this program, but at no time does X4 Pharma receive patient identifiable information. X4 Pharma receives contact information for healthcare providers who use this program. Genetic testing is available in the US and Canada only with the potential for expansion into other countries where third party genetic testing is permitted by local rules and regulations. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any X4 Pharma product.

1. Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K. Severe congenital neutropenias. Nat Rev Dis Primers. 2017;3:17032.